Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemifloxacin.

T. P. Le1, Y-Q. Xiong

  • 1Department of Medicine, Division of Infectious Diseases, Research & Education Institute, St. John's Cardiovascular Research Center, LAC-Harbor UCLA Medical Center, Torrance, California, USA. xiong@humc.edu

Drugs of Today (Barcelona, Spain : 1998)
|May 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Gemifloxacin, a novel fluoroquinolone antibiotic, shows enhanced activity against Gram-positive and Gram-negative bacteria. Its broad-spectrum efficacy and convenient administration make it valuable for treating various infections like pneumonia.

Area of Science:

  • Pharmacology and Microbiology
  • Antibacterial Agents

Background:

  • Gemifloxacin is a novel fluoroquinolone antibiotic.
  • It features a unique pyrrolidine derivative at the C-7 position.

Purpose of the Study:

  • To evaluate the spectrum of activity and potential of gemifloxacin.
  • To assess its efficacy against various bacterial pathogens.

Main Methods:

  • In vitro and in vivo studies were conducted.
  • Activity was assessed against Gram-positive, Gram-negative, and anaerobic bacteria.

Main Results:

  • Gemifloxacin demonstrated enhanced activity against Streptococcus pneumoniae and Staphylococcus aureus.
  • It showed excellent activity against Enterobacteriaceae and respiratory pathogens.

Related Experiment Videos

  • Potential in vitro activity against anaerobic bacteria was also observed.

    • Conclusions:

    • Gemifloxacin possesses a broad spectrum of activity, including against key respiratory pathogens.
    • Its favorable pharmacokinetic profile and tolerability suggest it is a valuable addition to treat infections such as community-acquired pneumonia and urinary tract infections.